# US 2026/0053912 A1 · Sterols as novel immunomodulatory agents and their use as vaccine adjuvants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0053912 A1
- Document ID: US20260053912A1
- Status: Published application
- Kind: A1
- Application number: 19/372,974
- Filed: 2025-10-29
- Published: 2026-02-26
- Earliest claimed: 2017-08-24
- Assignees: Ohio State Innovation Foundation
- Applicants: Ohio State Innovation Foundation
- Inventors: Abhay R. SATOSKAR; James R. FUCHS; Alan Douglas KINGHORN; Li PAN; Eric BACHELDER; Narasimham L. PARINANDI
- Web page: https://patentgrep.com/patent/US20260053912A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- C07J 73/003: {by oxygen as hetero atom}
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 39/008: Leishmania antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07C 401/00: Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
- C07J 7/002: {not substituted in position 16}
- C07J 9/00: Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J 13/005: {with double bond in position 16 (17)}
- C07J 63/008: {Expansion of ring D by one atom, e.g. D homo steroids}
- A61K 2039/55511: {Organic adjuvants}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07J: STEROIDS (seco-steroids C07C)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are methods of using immunomodulatory sterols as vaccine adjuvants.

## Claims

### Claim 1

A pharmaceutical composition comprising an immunomodulatory sterol having the following structure:
wherein each is independently a single or double bond, with the proviso that the compound does not include an allene;
wherein Ra is ORe and Rb is hydrogen, or Ra is hydrogen and Rb is ORe, or Ra and Rb together form a carbonyl, wherein Re is selected from hydrogen or a carbohydrate moiety, i.e., a monosaccharide, disaccharide, or trisaccharide;
Rc is hydrogen, C1-C12 alkyl or C1-C12 alkenyl, or Ra and Rb together form a carbonyl;
Rd a group having the formula X-Rf, wherein X is either absent or a carbonyl, and Rf is C1-C12 alkyl or C1-C12 alkenyl;
or a pharmaceutically acceptable salt or prodrug thereof, and a cancer antigen.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cancer antigen elicits a specific immune response against cancer cells expressing the antigen.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cancer antigen comprises a peptide.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cancer antigen comprises a tumor-specific antigen.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the tumor-specific antigen is encoded by a mutant cellular gene.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the mutant cellular gene is selected from an oncogene and a suppressor gene.

### Claim 7 (depends on 4)

The pharmaceutical composition of claim 4, wherein the tumor-specific antigen is a fusion protein resulting from an internal deletion or chromosomal translocation.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cancer antigen comprises a tumor-associated antigen.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cancer antigen is encoded by a viral gene.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cancer is specific for a cancer.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein the cancer is selected from carcinoma, lymphoma, blastoma, sarcoma, leukemia, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, neuroendocrine cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, brain cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, esophageal cancer, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, head and neck cancer, and combinations thereof.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein the immunomodulatory sterol has the formula:
wherein each is independently a single or double bond; wherein R1 is selected from C1-C12 alkyl and C1-C12 alkenyl; wherein R2 is selected from C1-C12 alkyl and C1-C12 alkenyl; wherein R7 is selected from hydrogen, hydroxyl, amino, and halogen; and wherein R8 is selected from hydrogen C1-C12 alkyl and C1-C12 alkenyl; or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein the immunomodulatory sterol has the following structure:
wherein
R1 is selected from C1-C12 alkyl and C1-C12 alkenyl.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein R1 is selected from:

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein the immunomodulatory sterol has the formula:

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein the immunomodulatory sterol is present in an amount from 0.1 to 100 μg.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, wherein the immunomodulatory sterol is present in an amount from about 1-25 μg.

### Claim 18 (depends on 1)

A method for vaccinating a subject in need thereof, comprising administering to the subject the composition according to claim 1.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the immunomodulatory sterol and antigen are administered in a single composition.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the immunomodulatory sterol and antigen are administered in separate compositions.
